Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HUM Stock Forecast 2025-2026
$252.04
Current Price
$30.31B
Market Cap
Buy 8
Hold 18
Sell 1
Wall St Analyst Ratings
Distance to HUM Price Targets
+40.1%
To High Target of $353.00
+16.1%
To Median Target of $292.50
-6.8%
To Low Target of $235.00
HUM Price Momentum
-9.4%
1 Week Change
-13.3%
1 Month Change
-12.5%
1 Year Change
-0.7%
Year-to-Date Change
-20.1%
From 52W High of $315.35
+21.8%
From 52W Low of $206.87
📊 TOP ANALYST CALLS
Did HUM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Humana is one of their latest high-conviction picks.
Latest HUM Stock Price Targets & Analyst Predictions
Based on our analysis of 39 Wall Street analysts, HUM has a neutral consensus with a median price target of $292.50 (ranging from $235.00 to $353.00). The overall analyst rating is N/A (N/A/10). Currently trading at $252.04, the median forecast implies a 16.1% upside. This outlook is supported by 8 Buy, 18 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Frank Morgan at RBC Capital, projecting a 40.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HUM Analyst Ratings
8
Buy
18
Hold
1
Sell
HUM Price Target Range
Low
$235.00
Average
$292.50
High
$353.00
Current: $252.04
Latest HUM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HUM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 10, 2025 | B of A Securities | Kevin Fischbeck | Neutral | Maintains | $300.00 |
| Oct 9, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $345.00 |
| Oct 7, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $347.00 |
| Oct 3, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $245.00 |
| Oct 3, 2025 | Guggenheim | Jason Cassorla | Buy | Reiterates | $N/A |
| Sep 22, 2025 | Evercore ISI Group | Elizabeth Suzuki | In-Line | Initiates | $295.00 |
| Sep 5, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $315.00 |
| Sep 5, 2025 | Bernstein | Lance Wilkes | Outperform | Maintains | $341.00 |
| Sep 2, 2025 | B of A Securities | Kevin Fischbeck | Neutral | Maintains | $312.00 |
| Aug 21, 2025 | RBC Capital | Ben Hendrix | Outperform | Maintains | $322.00 |
| Aug 14, 2025 | Argus Research | David Toung | Hold | Reiterates | $281.99 |
| Aug 14, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $344.00 |
| Jul 31, 2025 | Piper Sandler | Jessica Tassan | Neutral | Maintains | $272.00 |
| Jul 31, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $275.00 |
| Jul 31, 2025 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $277.00 |
| Jul 25, 2025 | Baird | Michael Ha | Neutral | Maintains | $297.00 |
| Jul 16, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $260.00 |
| Jun 17, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $280.00 |
| Jun 17, 2025 | B of A Securities | Kevin Fischbeck | Neutral | Maintains | $260.00 |
| Jun 12, 2025 | Barclays | Andrew Mok | Equal-Weight | Maintains | $268.00 |
Humana Inc. (HUM) Competitors
The following stocks are similar to Humana based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Humana Inc. (HUM) Financial Data
Humana Inc. has a market capitalization of $30.31B with a P/E ratio of 19.3x. The company generates $123.11B in trailing twelve-month revenue with a 1.3% profit margin.
Revenue growth is +9.6% quarter-over-quarter, while maintaining an operating margin of +3.6% and return on equity of +9.0%.
Valuation Metrics
Market Cap
$30.31B
Enterprise Value
$24.94B
P/E Ratio
19.3x
PEG Ratio
-1.0x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
+9.6%
Gross Margin
N/A
Operating Margin
+3.6%
Net Margin
+1.3%
EPS Growth
-19.7%
Financial Health
Cash/Price Ratio
+71.6%
Current Ratio
2.0x
Debt/Equity
70.6x
ROE
+9.0%
ROA
+4.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Humana Inc. (HUM) Business Model
About Humana Inc.
What They Do
Healthcare insurance provider focusing on Medicare solutions.
Business Model
Humana generates revenue through its diverse health insurance products, primarily in the Medicare Advantage market. The company offers tailored health plans for individuals and organizations, including government-sponsored programs and commercial employers. Its focus on wellness and preventive care helps to improve health outcomes for its members while maintaining profitability.
Additional Information
Based in Louisville, Kentucky, Humana is a key player in the U.S. healthcare system. The company is enhancing its digital solutions and forming partnerships to promote integrated care, which positions it favorably within the evolving healthcare landscape.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
65,680
CEO
Mr. James A. Rechtin M.B.A.
Country
United States
IPO Year
1981
Website
www.humana.comHumana Inc. (HUM) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Humana Beats Q3 Earnings on Premium Growth, Updates 2025 View
HUM tops Q3 earnings forecasts on strong premium growth, even as higher costs and lower memberships weigh on results.
Nov 05, 2025
By Zacks Equity Research
Analyst Blog
Can Humana Beat Q3 Earnings Estimates on Growing Premiums?
HUM aims for a Q3 earnings beat as rising premiums and solid service revenues offset higher costs and lower income.
Nov 03, 2025
By Zacks Equity Research
Analyst Blog
Select Medical (SEM) Surpasses Q3 Earnings and Revenue Estimates
Select Medical (SEM) delivered earnings and revenue surprises of +27.78% and +2.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 30, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Humana's third-quarter profit exceeded Wall Street estimates due to increased premiums.
Why It Matters
Humana's stronger-than-expected profits indicate robust demand and effective management, potentially boosting investor confidence and impacting stock performance positively.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Humana reported $195 million in profits for Q3, with medical cost trends aligning with the company's previous forecasts.
Why It Matters
Humana's $195 million profit and aligned medical cost trends indicate stable performance, potentially boosting investor confidence and stock valuation in the health insurance sector.
Source: Forbes
Market Sentiment:
Positive
Quick Summary
Humana's Q3 profit declined, and the company reduced its full-year earnings guidance due to rising medical costs impacting margins in its Medicare Advantage business.
Why It Matters
Humana's lower profit and reduced earnings guidance signal rising medical costs, which can negatively impact margins and shareholder value, indicating potential risk in the Medicare Advantage sector.
Source: WSJ
Market Sentiment:
Negative
Quick Summary
Humana has a "Hold" rating amid fair valuation and underperformance vs. the S&P 500. Q3 earnings exceeded expectations, but FY 2025 outlook is weak, with challenges in membership and regulations.
Why It Matters
Humana's "Hold" rating and poor FY 2025 outlook indicate potential stagnation, while rising costs and regulatory issues could impact future earnings, affecting share performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Humana Inc. will hold its Q3 2025 Earnings Call on November 5, 2025, at 8:00 AM EST, featuring key executives including the CEO and CFO.
Why It Matters
Humana's Q3 earnings call will provide insights into its financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Humana Reports Third Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted EPS Guidance
4 days ago
Quick Summary
Humana Inc. reported its consolidated pretax results and diluted EPS for Q3 2025, comparing them with Q3 2024, and also for the first nine months of 2025 versus 2024.
Why It Matters
Humana's quarterly earnings report impacts investor sentiment, indicating financial health and growth potential, influencing stock performance and investment decisions.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About HUM Stock
What is Humana Inc.'s (HUM) stock forecast for 2026?
Based on our analysis of 39 Wall Street analysts, Humana Inc. (HUM) has a median price target of $292.50. The highest price target is $353.00 and the lowest is $235.00.
Is HUM stock a good investment in 2026?
According to current analyst ratings, HUM has 8 Buy ratings, 18 Hold ratings, and 1 Sell ratings. The stock is currently trading at $252.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HUM stock?
Wall Street analysts predict HUM stock could reach $292.50 in the next 12 months. This represents a 16.1% increase from the current price of $252.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Humana Inc.'s business model?
Humana generates revenue through its diverse health insurance products, primarily in the Medicare Advantage market. The company offers tailored health plans for individuals and organizations, including government-sponsored programs and commercial employers. Its focus on wellness and preventive care helps to improve health outcomes for its members while maintaining profitability.
What is the highest forecasted price for HUM Humana Inc.?
The highest price target for HUM is $353.00 from Frank Morgan at RBC Capital, which represents a 40.1% increase from the current price of $252.04.
What is the lowest forecasted price for HUM Humana Inc.?
The lowest price target for HUM is $235.00 from at , which represents a -6.8% decrease from the current price of $252.04.
What is the overall HUM consensus from analysts for Humana Inc.?
The overall analyst consensus for HUM is neutral. Out of 39 Wall Street analysts, 8 rate it as Buy, 18 as Hold, and 1 as Sell, with a median price target of $292.50.
How accurate are HUM stock price projections?
Stock price projections, including those for Humana Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 4:28 AM UTC